Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
J Plast Reconstr Aesthet Surg ; 74(3): 480-485, 2021 03.
Article in English | MEDLINE | ID: mdl-33069605

ABSTRACT

INTRODUCTION: Contralateral prophylactic mastectomy has the potential to decrease the occurrence of cancer and reduce psychological burden. However, it is known that complications after bilateral mastectomy are higher compared with unilateral mastectomy. Our goal was to evaluate outcomes of immediate breast reconstruction in patients undergoing bilateral mastectomy and to compare complication rates between therapeutic and prophylactic sides. PATIENTS AND METHODS: Electronic medical records of patients with unilateral breast cancer who underwent bilateral mastectomy and immediate reconstruction with expanders were reviewed. Postoperative complications were compared between therapeutic and prophylactic mastectomy sides. RESULTS: Sixty-two patients were analyzed. The overall complication rate after both stages was 23.9% on the therapeutic side and 16.5% on the prophylactic side. Infection was the most common complication on both sides. All infections on the prophylactic mastectomy side were successfully treated with intravenous (IV) antibiotics (salvage rate of 100%), whereas 35.7% of infected tissue expander/implants on the therapeutic mastectomy side were explanted despite treatment. CONCLUSION: Careful counselling of patients undergoing elective contralateral prophylactic mastectomy is essential as complications can develop in either breast after reconstruction.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Mastectomy , Prophylactic Mastectomy , Prosthesis-Related Infections , Surgical Wound Infection , Unilateral Breast Neoplasms/surgery , Administration, Intravenous , Adult , Directive Counseling/methods , Electronic Health Records/statistics & numerical data , Female , Humans , Mastectomy/adverse effects , Mastectomy/methods , Middle Aged , Needs Assessment , Prophylactic Mastectomy/adverse effects , Prophylactic Mastectomy/methods , Prosthesis-Related Infections/epidemiology , Prosthesis-Related Infections/etiology , Prosthesis-Related Infections/therapy , Risk Assessment/methods , Surgical Wound Infection/epidemiology , Surgical Wound Infection/etiology , Surgical Wound Infection/therapy , Unilateral Breast Neoplasms/epidemiology , United States/epidemiology
2.
Aesthetic Plast Surg ; 42(1): 64-72, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29270693

ABSTRACT

INTRODUCTION: Removal of tissue expanders (TE) or implants is a dire consequence of breast reconstruction, and has the potential to halt the reconstructive efforts. Our goals were to characterize a cohort of patients with TE/implant removal, to perform a time-based analysis, and to review the bacteriology associated with explanted devices. MATERIALS AND METHODS: Review of a prospectively maintained database was performed to identify patients who underwent TE/implant removal. Patient characteristics, surgical technique, adjuvant therapies, indications, complications, culture results were obtained. Data were analyzed according to timing of explantation. RESULTS: A total of 55 TE and implants were removed in 43 patients. Reasons for explantation were infection (58%), patient request (22%), and wound-related complications (20%). The majority of explantations occurred after 30 days (62%), and after Stage I (81%). Median days to explantation was 62. Patients of older age (p = 0.01) and higher BMI (p = 0.02) were more likely to undergo explantation after Stage I. The most commonly cultured organisms were S. epidermidis (10.9%), S. aureus (10.9%) and P. aeruginosa (10.9%). Antibiotic resistance was commonly encountered for ampicillin, cefazolin, penicillin, and erythromycin. CONCLUSION: Infection is the most common reason for explantation after prosthetic breast reconstruction. Patients should be carefully monitored for a prolonged period of time after Stage I, as the majority of explantations occur in this stage but beyond 30 days. For oral treatment, fluoroquinolones and trimethoprim-sulfamethoxazole and for IV treatment a combination of vancomycin or daptomycin with piperacillin-tazobactam or imipenems/carbapenems appear to be appropriate choices according to our culture results. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .


Subject(s)
Breast Implants/adverse effects , Mammaplasty/methods , Prosthesis-Related Infections/drug therapy , Tissue Expansion Devices/adverse effects , Adult , Anti-Bacterial Agents/therapeutic use , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Cancer Care Facilities , Cohort Studies , Databases, Factual , Device Removal/methods , Female , Follow-Up Studies , Humans , Mammaplasty/adverse effects , Mastectomy/methods , Middle Aged , Prosthesis Failure , Prosthesis-Related Infections/diagnosis , Prosthesis-Related Infections/epidemiology , Reoperation/methods , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL